Sofgen Pharma

Sofgen Pharma P/B

The P/B (Price-to-Book Ratio) of Sofgen Pharma (PROCF) as of Nov 11, 2026 is -22.55. In the previous year, P/B (Price-to-Book Ratio) was 5,490.88 — a change of -100.41% (lower).

P/B

-22.55

YoY

-100.41%

Last updated:

P/B (Price-to-Book Ratio) of Sofgen Pharma is 2024 -22.55 . P/B (Price-to-Book Ratio) of Sofgen Pharma was 2023 5,490.88 . It decreases by -100.41% lower compared to the previous year.

The Sofgen Pharma P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2020
-4.51 USD
Jan 1, 2021
-16.70 USD
Jan 1, 2022
-31.86 USD
Jan 1, 2023
5,490.88 USD
Jan 1, 2024
-22.55 USD
The Sofgen Pharma P/B history
YEARP/BYoY
-22.55-100.41%
5,490.88-17,336.67%
-31.86+90.76%
-16.70+270.03%
-4.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sofgen Pharma Stock analysis

What does Sofgen Pharma do? Procaps Group SA generates revenue through its five business units: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics sells diabetes solutions, while Farma Procaps markets branded prescription drugs in Latin America. Softi Gel offers contract drug development and manufacturing services to third-party pharmaceutical companies. Vital Care produces consumer healthcare products, and Clinical Specialties focuses on complex drugs. The company's products include prescription drugs, nutritional supplements like omega 3 fish oils, and high-potency clinical compounds. Farma Procaps targets prescription drug markets in Latin America, selling branded products under its own name. Softi Gel serves third-party pharmaceutical companies by providing development and manufacturing services. Vital Care focuses on consumer healthcare products, and Clinical Specialties develops and markets complex drugs. The primary customers are healthcare providers, pharmaceutical companies, and consumers seeking specialized health solutions. The company's revenue streams are derived from prescription drug sales, contract manufacturing services, and consumer healthcare product distribution. Diabetrics and Clinical Specialties cater to medical professionals with specialized treatments, while Vital Care serves retail consumers through over-the-counter products. Softi Gel's services are contracted by other pharmaceutical firms seeking external development and manufacturing support. Sofgen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sofgen Pharma stock

P/B (Price-to-Book Ratio) of Sofgen Pharma is -22.55 in 2024.

P/B (Price-to-Book Ratio) of Sofgen Pharma changed from 5,490.88 to -22.55, representing a -100.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Sofgen Pharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Sofgen Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Sofgen Pharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Sofgen Pharma